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In English
The National Agency for Medicine has recently published its
strategy for 2006–2012 available at the website www.nam.fi
and posted to the representatives of stakeholder groups in
Finland and in the EU collaborative network.
Drawing up strategies is a present-day phenomenon. Sev-
eral agencies of the social and health care administration
such as the National Research and Development Centre for
Welfare and Health (STAKES), the National Public Health
Institute and the Institute of Occupational Health have
recently published their new strategies.
The phenomenon is international, at least in the
pharmaceutical field. The European Medicines Agency
(EMEA) concluded its own Road Map in December 2004,
extending to the year of 2010. The Heads of Medicines
Agencies Strategy Paper on the European Medicines Regula-
tory Network has also been under preparation as well as
strategies of many national regulatory agencies. 
Working out strategies for NAM has traditions going
back a decade. Despite the fact that the supervision of medi-
cines and medical devices is firmly based on the Finnish and
EU legislation, a strategy has been necessary. This is impor-
tant so that resources can be concentrated in a controlled
manner precisely on the issues on which special influence is
striven for. In particular, European collaboration has in
recent years become close and extensive to a degree making
it necessary to prioritise the targets of influence in a world of
restricted resources.
In its form, the strategy of NAM for 2006–2012 follows
the conventional features. It embodies the mission
statement, values, definition of clients and description of the
operational environment. The vision and strategic targets
point the way for future operations.
The statement of the aims envisioned for 2012 reveals
that NAM seeks to be a reliable and efficient regulatory
authority and a respected expert. NAM has a firm grasp of
the pharmaceutical policy discussions. In the EU
environment the expertise of NAM is known to its clientele.
In its focus areas of influence, in paediatric medicinal prod-
ucts and biological medicines, NAM is the co-operative part-
ner most preferred. NAM also seeks to provide an encourag-
ing working environment and promote the expertise of its
staff.
Among its strategic aims I would like to emphasise the
importance of the safety and correct use of medicines. NAM
aims to develop methods to utilise the existing healthcare
register and data resources in pharmacovigilance. The aim is
to create preparedness for  pharmaco-epidemiological studies
which could be set in motion at short notice.  The supervi-
sion of pharmacies will also be improved, with special atten-
tion being focused on the quality and form of drug informa-
tion and counselling. 
With its newly introduced strategy, NAM will continue
to develop as a strong and influential  partner in the Finnish
health care system in safeguarding the safety of medicines
and medical devices.
Operations steered by strategy 
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Interactions of inhaled glucocorticoids – 
CYP3A4 inhibitors increase the risk of systemic
adverse effects
Cytochrome P450 enzymes (CYP
enzymes) are important in the metabo-
lism of most medicinal substances.
CYP3A4, for instance, is involved in
the metabolism of every second medic-
inal substance. CYP3A4 is also impor-
tant for the metabolism of many glu-
cocorticoids, but it is nevertheless nec-
essary to recognise that the significance
of CYP3A4 varies among the different
glucocorticoids. 
Among the systemically used glu-
cocorticoids at least dexamethasone,
methylprednisolone and budesonide
are extensively metabolised by
CYP3A4, while this enzyme is of only
minor importance in the elimination
of prednisone and prednisolone (1-5).
CYP3A4 enzyme inhibitors include,
for example, several antifungal agents
of the azole group, several HIV
protease inhibitors, verapramil and dil-
tiazem among the calcium channel
blockers, and a number of macrolides
(Table). CYP3A4 enzyme inhibitors
increase the blood concentration of the
systemic glucocorticoids metabolised
with the aid of this enzyme up to
about 3 to 6-fold, which also signifi-
cantly increases the effects and risk of
adverse reactions of the glucocorti-
coids. Rifampicin and other enzyme
inductors in particular decrease the
plasma concentrations of glucocorti-
coids metabolised by CYP3A4, thereby
reducing their effect.
What about the proneness of
glucocorticoids to
interactions?
Inhaled glucocorticoids such as beclo-
methasone, budesonide and fluticasone
are generally used in the treatment of
asthma. Metered dosage produces a
good response in the lungs, and due to
the low dosage, the systemic adverse
reactions of glucocorticoids remain
minor. CYP3A4 appears to be an
important enzyme in the metabolism
of beclomethasone, budesonide and
fluticasone. As the bronchial mucous
membranes, unlike the small intestine,
do not contain significant amounts of
the enzyme (6–7), these inhaled gluco-
corticoids are hardly at all metabolised
in the lungs; instead they are absorbed
into the blood circulation. But when
used orally, budesonide and fluticas-
one, for example, are extensively
metabolised by the intestinal mucous
membrane and in the liver, even before
reaching the systemic blood circula-
tion, and therefore, when swallowed,
their concentrations in the systemic
blood circulation remain small and the
systemic effects minor.
Only about 10 to 25% of the
inhaled drugs reach the lungs, while
the main part of the dose remains on
the upper respiratory mucous mem-
branes and in the mouth and is swal-
lowed. Glucocorticoid reaching the
blood circulation via the lungs is not
metabolised until it reaches the liver,
whereas the portion of drug remaining
in the mouth and swallowed is inacti-
vated in a normal situation mainly by
the intestinal mucous membrane and
in the liver before ever reaching the
systemic blood circulation, thereby
failing to cause any systemic adverse
effects. The situation is nevertheless
radically changed if the patient uses
CYP3A4 enzyme inhibiting drugs
(Table). Some drugs used in the treat-
ment of HIV in particular and some
antifungal agents are potent CYP3A4
inhibitors. When these are used, there
can be a manifold increase in the sys-
temic (adverse) effects of inhaled glu-
cocorticoids as their normal presyste-
mic metabolism is inhibited and these
agents reach the blood circulation in
their active form. The half-lives of
these glucocorticoids are also likely to
be prolonged, which in itself increases
the risk of systemic reactions.
In a clinical trial, healthy
volunteers were given alternatively
either itraconazole (200 mg/day) or a
placebo for five days, followed by
inhalations of budesonide on the fifth
day of either of these phases. Plasma
budesonide concentrations were signi-
ficantly higher in the itraconazole
phase compared with the placebo
phase. Exposure to budesonide (plasma
budesonide concentration x time, i.e.
the AUC value) was increased on aver-
age 4.2-fold due to the effect of itra-
conazole (8). The halting of cortisol
excretion occasioned by budesonide
was significantly more pronounced in
the itraconazole phase compared with
the placebo phase. 
After this clinical trial was conduct-
ed in Finland, itraconazole has been
reported to have increased the systemic
adverse effects of budesonide in several
tens of patients (9–11). A 4-year-old
boy, for example, quickly developed
symptoms of Cushing’s syndrome as a
result of the concomitant use of itra-
conazole and inhaled budesonide (9).
All the CYP3A4 enzyme inhibitors
mentioned in Table evidently increase
the risk of adverse effects from budes-
onide, irrespective of whether it is used
orally, inhaled or via the nasal route.
Ritonavir, itraconazole, ketoconazole
and voriconazole in particular can be
expected to increase the effects of
budesonide significantly (12-14).
In addition to budesonide, the use
of other inhaled glucocorticoids is evi-
dently also associated with a risk of
interaction with CYP3A4 enzyme
inhibiting drugs, even though publish-
ed studies on the fact remain few in
number. The oral bioavailability of flu-
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ticasone, for example, is low due to its
extensive metabolism by CYP3A4 dur-
ing the absorption phase, and hence
CYP3A4 inhibitors can be expected to
increase the risk of systemic adverse
effects of fluticasone. Cases have been
published in the literature, in which
conventional inhaled or nasal adminis-
tration of fluticasone has caused Cush-
ing’s syndrome in patients on conco-
mi-tant ritonavir therapy (15–16).
Consequently, even though studies
have been conducted mainly on budes-
onide, there are justifiable grounds for
expecting a similar interaction with
inhaled fluticasone and beclometh-
asone.
Short-term concurrent use of
inhaled corticosteroids and CYP3A4
inhibitors lasting for a couple of days
is not generally expected to cause sig-
nificant systemic adverse effects. How-
ever, if the concomitant use is pro-
longed any further, for instance over 1
to 2 weeks, the possibility of glucocor-
ticoid systemic adverse effects should
be taken into consideration vis-à-vis all
inhaled steroids. It is worth bearing in
mind, that in some cases the CYP3A4
inhibitor can be replaced by another
one (e.g. itraconazole or ketoconazole
with terbinafine in the treatment of
fungal infections of the nails or skin).
Furthermore, efforts should be made
to reduce the inhaled steroid dose. In
patients on CYP3A4 inhibitor therapy
in particular rinsing the mouth and
then spitting out the rinsing liquid
after the intake of an inhaled steroid
can reduce the risk of systemic expo-
sure to the steroid.
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In English
CYP3A4 enzyme inhibitors
Ritonavir, saquinavir
Itraconazole, ketoconazole, voriconazole > miconazole ja fluconazole
Telithromycin, erythromycin, clarithromycin 
Amiodarone
Diltiazem, verapamil
Ciclosporin
Fluoxetine, fluvoxamine
Grapefruit juice
Itraconazole increased the mean total area under the plasma concentration-
time curve of inhaled budesonide. n=10 (Raaska et al. 2002).
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An elderly patient suffering from arter-
ial disease attends an out-patient clinic
after having had a fever for a couple of
days. It is discovered that he is dehy-
drated, there is no urinary excretion,
and the plasma creatinine concentra-
tion is high. It is also found out that
his medication includes renin-angio-
tensin system inhibitor (angiotensin-
converting enzyme inhibitor or angio-
tensin II receptor antagonist, the renal
effects of which are basically the same).
Despite vomiting he has conscientious-
ly taken his medication. It is often
only after having been asked about it
that he remembers having taken an
anti-inflammatory analgesic, because
he has believed it to be part of good
treatment of fever.
The situation described above is
not unusual. Why did the patient’s
kidneys stop functioning?
Renal effects of renin-angio-
tensin system inhibitors
Renin-angiotensin system inhibitors
are not nephrotoxic, on the contrary,
their effects that protect the kidneys
are used in the treatment of chronic
nephropathy. In certain situations,
however, the inhibition of angiotensin
II physiological effects will cause
impairment of the renal function.
The renal glomerular blood circula-
tion is exceptional: after the capillary
network urinary filtration, the blood
circulation continues in the artery, in
the efferent arteriole. The efferent arte-
riole is the most important site of
impact of angiotensin II in the kid-
neys. Due to autoregulation, the renal
circulation and glomerular filtration
remain steady despite even extensive
variations in the arterial pressure. This
is mainly regulated by the resistance of
the glomerular afferent arteriole. The
regulation works approximately at a
mean arterial pressure of 70 mmHg.
As the pressure is reduced below this
level, the angiotensin mediated con-
striction of the efferent arteriole joins
in to maintain the glomerular capillary
perfusion pressure unless the mechan-
ism is disturbed by medication. In
addition to this local compensation
mechanism being disturbed, the drug
is making the situation worse by
reducing the systemic blood pressure.
In addition to the reduced systemic
blood pressure, the renal perfusion
pressure is also diminished by poor
renal circulation as a result of renal
artery stenosis, renal diffuse atheroscle-
rosis or cardiac insufficiency. The fac-
tors often work together. The situation
is of course worsened by the diuretic
therapy these patients often need.
Renal effects of anti-inflamma-
tory analgesics
Adverse renal reactions of anti-inflam-
matory analgesics include acute inter-
stitial nephritis, chronic analgetic
nephropathy, fluid retention and
hypertension. This case only deals with
haemodynamically mediated acute
renal insufficiency.
In normal circumstances, adverse
renal effects of anti-inflammatory anal-
gesics are unlikely. The circumstances
change if the maintenance of renal per-
fusion pressure is dependent on the
effect of vasodilating prostaglandins.
These are the circumstances in chronic
renal insufficiency and, in the case of
healthy kidneys, in water loss and
hypotension. Disturbing this compen-
sation mechanism by prostaglandin-
synthesis-inhibiting anti-inflammatory
analgesic medication can even cause an
ischaemic tubular necrosis. Coxibs are
in this respect as harmful as conven-
tional anti-inflammatory analgesics.
Interaction
Both a renin-angiotensin system
inhibitor and an anti-inflammatory
analgesic, either on its own, may pro-
voke renal insufficiency in the situ-
ations described above. It should be
recognised that the risk is significantly
higher if they act together. Their
mechanism of action, unfortunately,
complement each other in such a situ-
ation. As a result of the vasodilating
prostaglandin inhibition, the afferent
arteriole is not dilated appropriately.
And as a result of the angiotensin II
inhibition, the efferent arteriole is not
constricted as it should be. Thus
glomerular capillary perfusion pressure
remains too low for the glomerular fil-
tration to work.
The situation is often made worse
by a third factor, a diuretic. In an Aus-
tralian study (Lopoz and Shenfield,
2005) an assay was made as a cross-
profile of 301 patients in an internal
medicine department in a teaching
hospital; their use of a renin-angio-
tensin system inhibitor, a diuretic and
an anti-inflammatory analgesic was
studied, including creatinine and esti-
mated creatinine clearance. The use of
two or more drugs was markedly asso-
ciated with renal insufficiency, even
though the multivariate analysis took
into account the effect of cardiac insuf-
ficiency and other diseases associated
with the use of these drugs.
In conclusion
Angiotensin inhibitors have justifiably
gained their role in the treatment of
hypertension and cardiac and renal dis-
eases. Problems could be cut down if
intervals of no medication were intro-
duced in water-loss situations. It is
important in particular to advise of the
risk of concomitant administration of
anti-inflammatory analgesics. Under-
standably, many patients believe the
drug to be harmless as it is available
without a prescription.
If a problem has risen, it is often,
at the initial stage, resolved with a
quick infusion of normal saline.
In English
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A man in his middle fifties was suffer-
ing from Parkinson’s disease diagnosed
as early as the beginning of the 1990s.
He had suffered from neurological
symptoms in his adolescence. The dis-
ease was kept under control for a long
time by medication with levodopa/car-
bidopa + selegiline, but the symptoms
became worse at the beginning of
2002, and consequently the
medication was changed and
pramipexole administered as an
adjunct, which at the end of spring
had reached the level of 0.7 mg x 3.
Efforts were made to increase the dose
further due to the symptoms manifest-
ed, but as a result of compulsive move-
ments the dose was reduced to the
baseline level. The other medication
consisted of levodopa/benserazide
100/25 a quarter of a tablet twice a
day, and a depottablet for the night
and selegiline 10 mg x 1. The motor
symptoms were relatively well
controlled with these drugs, but in
autumn 2002 the patient, had started
to gamble and managed to waste his
relatively large savings in a short period
of time. Pramipexole was replaced by
ropinirole, and the urge to gamble dis-
appeared.
There have been about 30 cases in
the literature where the patient has
acquired a new symptom of compul-
sive gambling, or where a previous
symptom has become worse. It is sug-
gested that its prevalence in advanced
Parkinson’s disease is as high as 5%.
This figure emanates from Spanish
material: 12 out of 250 patients suffer-
ing from Parkinson’s disease fulfilled
the disease classification criteria DSM-
IV. The suggested prevalence in the
normal population is 0.3 to 1.5%.
The symptom is usually associated
with the introduction or with the use
for a while of dopaminergine/ dopam-
ine agonist. The delay has, however,
occasionally been even longer. The
drugs frequently mentioned include
pramipexole or ropinerole, but the
symptom has also been reported, for
example, with bromocriptine. In the
North-American adverse event report-
ing system, AERS, the algorithm used
for searching for data finds a signal
relating to compulsive gambling given
for pramipexole, bromocriptine, the
combination of carbidopa/levodopa,
ropinirole, levodopa alone and pergol-
ide, but none is found for any dopam-
ine antagonist. This confirms the sug-
gestion that dopamine and dopaminer-
gic drugs as a group, cause such a
harmful reaction.
In the majority of cases, patients
have described the symptoms as
appearing during the ’on’ stage. It has
also been suggested that the symptom
could occur irrespective of medication,
because a couple of patients exhibited
symptoms during stable medication,
and reducing the dopaminergic med-
ication did not make the symptoms
disappear. This is interesting, albeit
somewhat contradictory. The psychi-
atric symptoms of Parkinson’s disease
indicate a relative deficiency rather
than an excess of dopamine in the
pleasure system (depression, anhedo-
nia, apathy, anxiety).
The specific adverse reactions
described also include increased sexual-
ity, hypomania and obsessive-compul-
sive symptoms, with the last two of
which compulsive gambling has been
associated. The symptom is neverthe-
less described without a distinct mania
or hypomania. 
About 15 to 30% of Parkinson’s
disease sufferers develop dementia,
while personality changes and
psychoses are also possible, and as a
result, various other types of odd
behaviour are of course possible. To
complicate matters, compulsive gam-
bling while the patient is suffering
from Parkinson’s disease has been asso-
ciated with alcohol abuse by the
patient, (antiparkinsonian) drug
dependence, unnatural jealousy and
also depression and anxiety. It has sim-
ilarly been suggested that compulsive
gambling could be an attempt to com-
pensate the hypodopaminergic state of
the brain’s prize system: gambling
would therefore be an external self-
treatment for the deficiency in the
internal system.
Compulsive gambling is mentioned
in the SPC for pramipexole. 
The primary treatment is probably
a reduction in the dose or a change of
medication, while counselling and
therapy have also been suggested.
Informing the patient’s next of kin is
definitely recommended. According to
one case report, the symptom was suc-
cessfully treated, but not without
adverse reactions, even with
risperidone, which of course is an
effective dopamine antagonist. 
Compulsive gambling due to antiparkinsonian
agent?
In English
Tapani Vuola ADR News
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About 5 to 6% of Finns suffer from
asthma. It has constantly grown more
common over the past 20 years. It is
suggested that about 400,000 Finns
suffer from chronic obstructive
pulmonary disease. In 2004, about
212,117 Finns were entitled to special
reimbursement for drugs for chronic
pulmonary asthma, and chronic
obstructive pulmonary diseases similar
to it. For the drugs most commonly
used for these diseases, reimbursement
was given to 167,904 individuals (1).
According to the classification of
the Social Insurance Institution in Fin-
land, the group of chronic pulmonary
asthma and similar chronic obstructive
pulmonary diseases comprehends asth-
ma, chronic obstructive bronchitis
and/or pulmonary emphysema,
pulmonary cystic fibrosis, chronic
unspecified airways narrowing and its
complications, and paediatric
bronchopulmonary dysplasia.
According to its severity and need
for treatment, asthma is divided into
four categories: sporadic, mild, moder-
ate and severe (2, 3). A significant pro-
portion of asthma is mild and needs
no daily medication. In the 2004 asth-
ma appraisal, about 48% of anti-asth-
ma drug users were grouped by severi-
ty in the mildest category. In accord-
ance with the special reimbursement
criterion of the Social Insurance Insti-
tution, pulmonary asthma should be
considered a severe and long-term disease,
when regular medication has lasted for at
least half a year and is still continuing.
Because initially effective medication
may be followed by symptom-free stages
of the asthma, the need for medication
should be reassessed from time to time.
Sporadic or mild asthma consequently
does not necessarily fulfil the condit-
ions for special reimbursement, or at
least not permanently. In accordance
with GINA classification of severity,
mild or moderate asthma can, never-
theless, be long-term (2).
Chronic obstructive pulmonary
disease can be divided into three cate-
gories according to its severity: mild
(75 %), moderate (requiring medical
treatment, 20 %) and severe (requiring
hospitalisation annually, 5 %). Drug
treatment for chronic obstructive pul-
monary disease and other obstructive
pulmonary diseases can entitle to spe-
cial reimbursement on the same princi-
ples as drug treatment for asthma.
Treatment recommendations
for asthma
According to Finnish and foreign treat-
ment recommendations, the most
important primary drug for asthma is
an inhaled glucocorticoid (3, 4).
According to several comparisons, cor-
ticosteroids are considered more effec-
tive inflammatory inhibitors than the
more recent drugsdeveloped for asth-
ma in particular, such as leukotriene
receptor antagon-ists, theophylline or
cromones (e.g. 4-6). In some patients,
a steroid may in mild asthma be
replaced by a leukotriene receptor
antagonist or other anti-inflammatory
drug.
It is recommended that an inhaled
steroid be combined as necessary with
an adjunct therapy with a short-acting
beta-2 agonist. The need for its use
may to some extent be considered an
indicator of the inadequacy of the anti-
inflammatory medication (3). For per-
sistent moderate and severe symptoms,
and for exacerbations, a long-acting
beta-2 agonist and theophylline,
leukotriene receptor antagonist or oral
prednisolone is recommended as an
adjunct to a corticosteroid treatment.
Some studies have supported a combi-
nation treatment of a corticosteroid
and a long-acting beta-2 agonist (e.g.
7). In some studies a long-acting beta-
2 agonist as adjunct therapy has been
found more effective than a leukotrien
receptor antagonist when corticoster-
oid therapy alone is not sufficient (8).
FDA has recommended that long-
acting beta-2 agonists should only be
used in patients in whom a desired
response to other anti-asthmatic drugs,
such as a small or a medium dose of a
corticosteroid, has not been achieved
(9).  Despite the fact that the use of a
beta-2 agonist has been criticised for
its high price, it may occasionally be
found to be cost-effective. A number
of studies claim formoterol therapy to
be more cost-effective than salmeterol
therapy (10,11). 
In the year 2000, there was fairly
good compliance with the national rec-
ommendations for treatment in
Finland, at least judging by the conti-
nuity of treatment and general use of
corticosteroids (12). Nevertheless,
adult asthma patients had several drugs
in use: an average of a total of 4.5 pre-
scription drugs, about 2.4 of which
were anti-asthmatics (13). In 2004, the
average annual anti-asthmatic drug
costs for men were 516 euros and
those for women 529 euros (1).
The aims and methods of
study
The aim was to determine which pre-
scription drugs were used in the treat-
ment of chronic pulmonary asthma
and chronic obstructive pulmonary
In English
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– drug consumption in Finland 2004 
diseases similar to it, and how the use
and costs of the drugs were divided
regionally and socio-economically in
the year 2004. Medical treatments
were also reviewed on the basis of
national treatment recommendations.
In March 2006 a new national recom-
mendation for the current treatment of
asthma was published, while the drug
combinations in the material have pri-
marily been compared with treatment
recommendations in force in 2004.
The aim of the study was thus to
describe how the use of anti-asthmatic
drugs in Finland is divided in relation
to level of income and education, age,
sex, mother tongue and employment.
The study was conducted as a reg-
ister study using the data of the Social
Insurance Institution and Statistics
Finland. In this paper, a combination
product refers to product which con-
tains an inhaled steroid and a long-act-
ing beta-2 agonist, or an inhaled anti-
cholinergic and a short-acting beta-2
agonist (ATC Code R03AK).
Use of the drugs
The subject material consisted of
92,100 individuals, i.e. 55% of those
who were receiving special reimburse-
ment for their anti-asthmatic drugs in
2004. The proportion of women
among the subjects was 58%. Accord-
ing to the data, the prevalence of asth-
ma and other obstructive pulmonary
diseases was slightly higher in female,
older, Finnish speaking subjects living
in smaller municipalities than in male,
younger subjects, speaking other lan-
guages and living in larger municipali-
ties. 
The subjects in the study were dur-
ing 2004 using between one and
eleven different anti-asthmatic drugs, a
median of 2.3 drugs, which corres-
ponds well with research results pre-
sented previously (12). Less than
20,000 individuals (20% of the
subjects) used an inhaled steroid
together with a short-acting beta-2
agonist. This was also the most com-
mon medication in each age group.
Furthermore, an inhaled steroid alone,
a combination product alone or a
combination product together with a
short-acting beta-2 agonist, were each
used by about 10,000 individuals
(about 10% of the subjects). Even
here, the divisions into age groups
were relatively even. Nor did treatment
practices differ between the sexes or
the language groups.
The majority of the medications
complied well with the treatment rec-
ommendations. The fifth most com-
mon medication was, nevertheless, a
short- or long-acting beta-2 agonist
alone without any anti-inflammatory
medication for the entire year. About
4,000 patients (4%) were treated in
this way. The treatment does not com-
ply with the recommendations, except
perhaps for sporadic or mild asthma,
when the sufferer sporadically uses a
course of steroid, or for sporadic symp-
toms of chronic obstructive pulmonary
disease. In this case there may not nec-
essarily be grounds for special reim-
bursement for the medication, since
according to the treatment recommen-
dation a patient with chronic moderate
or severe asthma should continuously
use an inhaled steroid. Similarly, in
chronic obstructive pulmonary disease
with continuous symptoms continuous
anticholinergic medication or similar
should be used. These 4,000 individu-
als had nevertheless entitlement to spe-
cial reimbursement for asthma for
about 5 to 6 years longer than individ-
uals who on average had used the four
most common medications.
The most common anti-inflamma-
tory medications included an inhaled
steroid alone (38% of the subjects in
the study), a combination product
alone (21%), an inhaled steroid com-
bined with a combination product
(6%) and an oral steroid together with
a combination product (5%). Almost
5,000 individuals (5% of the subjects)
did not use a steroid, leukotriene
receptor antagonist or theophylline. A
total of 54,000 individuals used an
inhaled steroid during the year: 26%
of them used beclomethasone, 36%
budesonide and 34% fluticasone. Over
3% used several of these products,
which is probably explained by the
change in medication that took place
during the year under review.
Among the bronchodilating med-
ications, the most common ones
included a short-acting beta-2 agonist
alone (30% of the subjects), a short-
acting beta-2 agonist together with a
salmeterol combination product (14%)
and a salmeterol combination product
alone (9%). About 15,000 individuals
(16% of the subjects) did not use any
beta-2 agonist or combination
product.
Drug costs 
The annual anti-asthmatic drug costs
per person were 533 euros on average
(men 529 euros with a median of 368
euros, and women 536 euros with a
median of 374 euros, no statistically
significant difference). Patients using
combination products and/or long-act-
ing beta-2 agonists had the most costly
drug treatment.
The anti-asthmatic drug costs were
significantly lower (a median of 386
euros) for users of an inhaled steroid
compared with those using an oral
steroid alone (890 euros) or both an
inhaled and an oral steroid (823
euros). This is probably due to the fact
that in the milder forms of the disease
an inhaled steroid alone is the most
commonly used, and the amount and
frequency of administration is reduced.
Among the inhaled steroid users, the
average costs borne by users of beclo-
methasone were about 350 euros/per-
son/year, budesonide 454 euros/per-
son/ year and fluticasone 522 euros/
person/year. Using a leukotriene recep-
tor antagonist and/or theophylline as
an adjunct therapy to a corticosteroid
added to the drug costs.
On reviewing the drug selection by
ATC groups, there were no significant
differences between employment sitau-
ation groups. The anti-asthmatics of
pensioners (636 euros/year) were on
average more costly, and those of chil-
dren (262 euros/year), students (384
euros/year) and conscripts/completing
civil service (297 euros/year) less costly,
on average compared with those of
employed individuals (483 euros/year)
and the unemployed (510 euros/year).
No differences were found in medica-
tion or costs between the various levels
of education and income.
Use of long-acting beta-2-ago-
nists and combination
products
Almost 48,000 individuals (52% of
the subjects in the study) were using
salmeterol and/or formoterol and/or a
combination product containing these.
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This was considerably more than the
proportion among the subjects in 2000
in the study by Ikäheimo et. al. (13),
when long-acting beta-2 agonists or
combination products containing them
were used by about 30% of the asthma
sufferers studied.
Salmeterol and/or a combination
product containing it was used by
almost twice as many subjects as those
who used formoterol and/or a combi-
nation product containing it. Both of
these long-acting beta-2 agonists were
used by over one percent of the sub-
jects. About half of those using a com-
bination product alone were using a
combination product of salmeterol and
a third were using a combination
product of formoterol. The rest were
using an anticholinergic combination
product containing a short-acting beta-
2 agonist or several different products
during the year.
The costs of anti-asthmatic drugs
were significantly higher in those who
used salmeterol and/or a combination
of salmeterol (836 euros/person/ year)
or formoterol and/or a combination of
formoterol (686 euros/person/year) or
both (1,111 euros/person/year) than in
those who used a short-acting beta-2
agonist or an anticholinergic combina-
tion product containing it (277
euros/person/ year), or in those who
used no airways-dilat-ating drug at all
(210 euros/person/ year). Those, who
used salmeterol and/or a combination
of salmeterol, and also used short-act-
ing beta-2 agonists or anticholinergic
combination products containing
these, incurred costs of 932 euros on
average, whereas without the short-act-
ing beta-2-agonists the costs were 680
euros. The corresponding costs borne
by users of formoterol and/or a combi-
nation of formoterol were 800 euros
and 576 euros.
In the whole country, combin-
ations of salmeterol (R03AK06) and of
formoterol (R03AK07) were used by
28% and 15%, respectively. 
A review by districts shows that the
use of combination of salmeterol was
distinctly more common in all other
hospital districts except that of Ahve-
nanmaa, where 30% of the patients
used formoterol and only 1%
salmeterol.
The proportion of users of salme-
terol (R03AC12) in the whole country
was almost the same as that of users of
formoterol (R03AC13), about 3%.
There were regional differences
between the users of long-acting beta-2
agonists. Salmeterol was used more fre-
quently in Länsi-Pohja or Lappi and
less frequently in Ahvenanmaa than
formoterol. 
Conclusion
In the main, the treatment of asthma
complied with the national treatment
recommendations. Even though the
treatment mostly appears appropriate,
both under-medication and over-med-
ication are apparent. 
The long-acting beta-2 agonist or
its combination product was used sig-
nificantly more commonly in 2004
compared with 2000, and combination
products were sometimes used even
alongside a separate inhaled steroid or
a long-acting beta-2 agonist.
The subjects in the study were on
average each using 2.3 drugs, the cost
of which was 533 euros per year. The
total annual anti-asthmatic drug costs
of all 92,100 individuals were about
49 million euros, for which reimburse-
ments were made to the amount of
over 35 million euros. The real
percentage of reimbursement was
therefore about 72%. The highest drug
costs were borne by individuals, who
used a long-acting beta-2 agonist
and/or its combination product.
The medical treatment of asthma
did not show significant differences
between ages, the sexes, levels of edu-
cation or income, employment status
or the size of the municipality of
domicile. There were, however, big dif-
ferences between the use of long-acting
beta-2 agonists and combination prod-
ucts containing them.
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It is not always self-evident which
group the product belongs to, since
many products may be on the border-
line of medicinal products, of cosmet-
ics and of food products. The entrepre-
neur should in that case seek to clarify
the status, for example by submitting
an application for classification of the
product in the National Agency for
Medicines. NAM then makes an evalu-
ation and decides whether the product
should be considered a medicinal
product.
Medicinal products are required to
have a marketing authorisation or to
be registered in accordance with the
Medicines Act before they are intro-
duced on to the market. Preconditions
for a marketing authorisation of a
medicinal product are, among others,
that it is effective as a medicine and
safe for use. The Medicines Act also
covers herbal medicinal products with
marketing authorisation, traditional
herbal medicinal products which ought
to be registered, and homoeopathic
products. Herbal medicinal products
with marketing authorisation can be
sold only in a pharmacy. Registered
traditional herbal medicinal products
and homoeopathic products may be
sold even elsewhere.
Natural products and their
marketing
The number of natural products on
the Finnish market is continuously
growing. There is no legislation that
covers natural products, while the term
is usually interpreted by the consumer
to mean either herbal medicinal prod-
ucts regulated by the Medicines Act, or
food supplements covered by foodstuff
legislation. Only a fraction of products
sold in health food shops are registered
traditional herbal medicinal products.
According to the Medicines Act,
only medicinal products referred to in
the Act may be sold as medicines. The
foodstuff legislation also prohibits any
mention of the foodstuff properties
relating to the prevention, treat-ment
or curing of diseases. Marketing of
food supplements is, however, very
varied, and they are often presented
with medicinal claims.
NAM does not supervise the intro-
duction on to the market and the mar-
keting of foodstuffs. The supervision
of marketing of herbal medicinal prod-
ucts and homoeopathic and anthropo-
sophical products covered by the Med-
icines Act falls, however, within the
remit of NAM.
What is a medicine, and why?
According to the Medicines Act, a
medicine has a pharmacological effect
or medicinal purpose of use. Section 3,
paragraph 3 of the Medicines Act was
introduced to clarify the situation
relating to the so-called border-line
products. When the product fulfils the
conditions of definition as a medicine
in accordance with the Medicines Act,
while it may also be under other legis-
lation, it is the Medicines Act which is
primarily applied. Classification as a
medicine is product-specific and based
besides on the product composition,
also on the intended purpose of use, in
accordance with the definition of a
medicine in the Medicines Act .
Composition and effect of the
medicinal product
According to the Medicines Act medi-
cine has a pharmacological, immuno-
logical or metabolic mechanism of
action, due to which it may be used to
modify, correct or restore physiological
functions. Classification is typically
sought from NAM for products which
contain herbs  used traditionally in one
or other part of the world, and the
availability of reliable information
about them varies. Classification is
often also sought for products which
contain a well-known herb, e.g.
ginseng or glucosamine, a substance on
the medicines list in Finland.
Research results on the pharmaco-
logical effects are seldom available of
the product to being classified. The
evaluation of the product’s pharmaco-
logical properties is largely based on
the information available on the sub-
stances contained in the product. The
classification procedure takes into
account primarily the information sup-
plied by the applicant as well as infor-
mation available in the scientific litera-
ture.
Medicines list
NAM in Finland maintains a medi-
cines list as a guideline. The list is not
comprehensive. The list is updated
every three years as new medicines are
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Correct and safe use of natural products
When an entrepreneur introduces a new product on to the Finnish market it is the entrepreneur’s responsibility to find out
the legislation that covers the product and the legal requirements relating to it and its marketing.
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introduced and as classification deci-
sions are made on medicinal
substances. Should a substance not be
included in the list, it does not mean
that a product which contains the sub-
stance could not be classified as a med-
icinal product.
The substances and herbs included
in the list have documented pharmaco-
logical properties and are or have been
used as medicines. It is likely that a
product containing these substances
with pharmacological properties will
be classified as a medicinal product.
The list also contains substances which
can be added to foodstuffs, for exam-
ple, aromatic agents and preservatives.
If a product sold as a foodstuff
contains substances included in the
list, the use of the product should be
based otherwise than on its pharmaco-
logical effect.
Medicinal use
Medicinal use according to the Medi-
cines Act includes prevention, allevia-
tion or curing of diseases or their
symptoms. A product which, based on
its pharmacological effect, is used in
attempts to modify the physiological
functions, also has a medicinal use.
The name of the product, package
information text, presentation and
intended purpose of use and the mar-
keting material are issues on which the
evaluation by NAM as to whether the
intended use of the product is medici-
nal is made.
It is likely, in our Internet era, that
a consumer will be looking for prod-
ucts and product information abroad.
The classification procedure therefore
also takes into account the marketing
of the product in other countries. In
the evaluation of product presentation,
the image the consumer is likely to
acquire concerning the product is
essential.
Medicine
A product classified as a medicine may
not be for sale as a foodstuff. Before
the medicinal product is introduced on
to the market, a marketing authorisa-
tion or registration must be applied
for.  At this stage of an application
relating to herbal medicinal products it
is determined whether the product ful-
fils the preconditions of the Medicines
Act set for traditional herbal medicinal
products or whether it should be con-
sidered a homoeopathic product.
A product classified as a medicinal
product is not automatically granted
marketing authorisation or
registration. The application procedure
for marketing authorisation and regis-
tration will also establish whether the
product fulfils the requirements set by
the Medicines Act relating to efficacy
and safety, for example.
Not a medicine = a safe food-
stuff?
If the outcome of the classification is
that the product is not a medicine,
according to the opinion of NAM it
may be introduced on to the market as
something other than a medicinal
product. However, a decision on classi-
fication is not a pronouncement on
the (other) product group that the
product belongs to, nor is it a declara-
tion on whether the product is safe to
use as a foodstuff.
When assessing the safety of medi-
cines, the risk-benefit balance in the
approved indication is essential. NAM
is not responsible for the supervision
of the safety of foodstuffs. NAM’s
decision on the classification does not
therefore rule out the responsibility of
the entrepreneur to ensure that the
product complies with another legisla-
tion, for example the foodstuff legisla-
tion. The entrepreneur is responsible
for ensuring that the product, when
used in the amount given in the
instructions for use, is appropriate as a
foodstuff and harmless to human
health.
Products on the EU internal
markets
Classification is often necessary at the
time of import of the product into the
country. The issue is often raised about
the free movement of goods within the
EU internal markets. However, this
principle is not applied to medicinal
products, and the import of medicinal
products  is restricted. Restriction of
the import of medicinal products and
the procedure of marketing authorisa-
tion or registration have been consid-
ered necessary to protect public health.
The principle of free movement in
relation to medicines has been taken
into account when drawing up the EU
common marketing authorisation and
registration procedures. It is the
responsibility of the national drug reg-
ulatory authorities to evaluate and
decide which products are considered
to be covered by the Medicines Act.
The classification as a medicinal prod-
uct is not intended to hinder the intro-
duction of a natural product on to the
market. Instead, the classification is an
attempt to ensure that, prior to its
being introduced on to the market, a
medicine, whether it is mild or strong,
from nature or synthetic, is safe for the
consumer to use and is marketed for
the approved use.
The definition of a medicine in the
Finnish Medicines Act is implemented
of an EU Directive. Drug regulatory
authorities in other EU countries are
also drawing a line between medicines
and other products. Further informa-
tion on the issues is found on the
Swedish Medical Products Agency’s
website (http://www.lakemedels-
verket.se/Tpl/NormalPage____3447.as
px) and in the guidebook published by
the Medicines and Healthcare products
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Regulatory Authority in UK, MHRA,
’A Guide to what is a Medicinal Prod-
uct’ (http://www.mhra.gov-uk).
Collaboration of authorities in
Finland
In Finland, the foodstuff products reg-
ulatory authority, the Finnish Food
Safety Authority (Evira), the customs
and the NAM collaborate in respect of
the control of border-line products.
The drug regulatory authorities and
foodstuff regulatory authorities of the
Nordic countries exchange data on
classification issues and work in collab-
oration to apply common principles in
the classification of border-line prod-
ucts.
The control of foodstuff products
marketing will become clearer with the
introduction of a Decree on nutrition-
al and health claims which is being
prepared in the EU at present. A com-
mon practice in respect of marketing
of  foodstuffs will not, however,
change the evaluation of pharmacolog-
ical properties and medicinal purpose
of use, which will remain to be carried
out by NAM.
Correct information for
consumers
The consumer often has the impres-
sion that diseases can be treated natu-
rally and safely with a natural product.
Herbal medicinal products are safe to
use for the approved indication. The
purpose of food supplements is to
complement the diet and their effect
can be nutritional or physiological.
When attempts are made to modify,
correct or restore the physiological
functions, product in question is medi-
cine.
The entrepreneur has the responsi-
bility for the sale and marketing of the
product in accordance with the legisla-
tion that covers it. Pharmaceutical pro-
fessionals play an important role in
communicating correct information
about the product to consumers. In
pharmacies, for example, reliable and
expert information is supplied on med-
icinal products. Pharmaceutical profes-
sionals through their training and edu-
cation, are familiar with the medicines
regulation, the development of medi-
cines and the risks associated with the
use of medicines. It is professionalism
to be able to differentiate a medicinal
product and a foodstuff product from
each other and to know how to com-
municate the information to the con-
sumer.
More information on classification
http://www.nam.fi/english/pharma
_industry/classification/index.html
Application for classification
Classification should be applied for
by submitting a signed written
request.
The request for classification and
associated enclosures should include:
• name of the product
• dosage form (e.g. tablet, drops)
• comprehensive composition (all
the substances contained in the
product with quantities given per
unit of dosage)
• size of package
• intended purpose of use
• dosage (for adults and children,
or possible age restrictions)
• package labelling
• any decision or statement of clas-
sification by drug regulatory
authorities in another EU coun-
try
The application for classification
should also include copies of package
labelling texts and material used in
the marketing of the product.
Full contact information of the appli-
cant should also be given in case of a
query for further details.
The application for classification
should be sent to 
Registry Office 
National Agency for Medicines 
P. O. Box 55
FI-00301 Helsinki
Finland
The cost of the decision is 85 euros,
and the processing time is usually a
minimum of 1 to 2 months.
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